BK Virus Nephropathy in Renal Transplant Recipients in Kuwait: A Preliminary Report

Nampoory, M.R.N.; Johny, K.V.; Pacsa, A.S.; Nair, Prasad; Said, Tarek; Halim, Medhat A; Francis, Issam M.; Samhan, M.; Mousawi, M.S.A. Al; Dalawi, A.; Szücs, György; Al‐Nakib, W.

doi:10.1016/j.transproceed.2005.08.018

Cited by 15 publications

(15 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Limaye et al (51) reported a 50% graft failure rate by the end of follow-up in four patients with PVAN but the graft failure rate was not reported for the non-PVAN group. Similarly, Nampoory et al (52) and Vasudev et al (20) demonstrated graft failure rates of 5% and 46%, respectively, in patients with PVAN, but the failure rate of patients with non-PVAN was not reported in either study. In the remainder of the studies, graft failure occurred in 0% to 67% by last follow-up (49, 54, 56 -60, 62, 64, 65, 67, 70).…”

Section: Study Qualitymentioning

confidence: 77%

“…In the remaining studies, viremia cleared in 40% to 96% (48,49,51,56) and viruria cleared in 7% to 80% (49,52,53,59,67) after immunosuppression reduction.…”

Section: Study Qualitymentioning

confidence: 96%

“…Immunosuppression Reduction Alone One randomized controlled trial (14), seven cohort studies (20, 48 -53), and 13 case series (54, 56 -60, 62-65, 67, 69, 70) examined the effect of maintenance immunosuppression reduction alone in the treatment of BK virus ( Table 2). Discontinuation of mycophenolate mofetil or azathioprine (14,53,54,60,67) and reduction of immunosuppression by 25% to 50% (20,48,51,52,57,58,62,64,65) were common strategies used. In six studies, immunosuppression reduction by 50% was the treatment of choice (48,50,52,57,65,70).…”

Section: Study Qualitymentioning

confidence: 99%

“…Discontinuation of mycophenolate mofetil or azathioprine (14,53,54,60,67) and reduction of immunosuppression by 25% to 50% (20,48,51,52,57,58,62,64,65) were common strategies used. In six studies, immunosuppression reduction by 50% was the treatment of choice (48,50,52,57,65,70). Switching immunosuppression (e.g., tacrolimus to cyclosporine) was also frequently used (49,53,54,57,60,(62)(63)(64)69).…”

Section: Study Qualitymentioning

confidence: 99%

See 3 more Smart Citations

Treatment of Polyomavirus Infection in Kidney Transplant Recipients: A Systematic Review

et al. 2010

View full text Add to dashboard Cite

BACKGROUND.: Polyomavirus-associated nephropathy (PVAN) is an important cause of kidney graft loss but there is no consensus on its management. This study aimed to systematically document all published treatments for PVAN to determine the most effective therapy. METHODS.: A computerized search in MEDLINE, EMBASE, and Cochrane databases (1950-2008) was performed. References from review articles and published abstracts from the American Transplant Congress (2005-2008) were also included. Study selection criteria included (a) population: adult (>18 years) kidney-only, primary or repeat renal transplant recipients; (b) setting: polyoma viruria, viremia or biopsy-proven PVAN or both; and (c) treatment: immunosuppression reduction alone or with adjuvant agents. The primary outcome was graft failure rate, and secondary outcomes included acute rejection rate, elimination of viruria and viremia, graft function, patient survival, and adverse events. RESULTS.: Of 555 identified citations, 40 studies examining the effect of immunosuppression reduction alone or in combination with cidofovir, leflunomide, intravenous immunoglobulin, or ciprofloxacin were included for appraisal. Pooled results found a death-censored graft loss rate of 8/100 patient-years for immunosuppression reduction alone and 8 and 13/100 patient-years for the addition of cidofovir or leflunomide, respectively. CONCLUSIONS.: There does not seem to be a graft survival benefit of adding cidofovir or leflunomide to immunosuppression reduction for the management of PVAN. However, the evidence base is poor and highlights the urgent need for adequately powered randomized trials to define the optimal treatment of this important condition.

show abstract

Section: Study Qualitymentioning

confidence: 77%

“…In the remaining studies, viremia cleared in 40% to 96% (48,49,51,56) and viruria cleared in 7% to 80% (49,52,53,59,67) after immunosuppression reduction.…”

Section: Study Qualitymentioning

confidence: 96%

Section: Study Qualitymentioning

confidence: 99%

Section: Study Qualitymentioning

confidence: 99%

See 2 more Smart Citations

Treatment of Polyomavirus Infection in Kidney Transplant Recipients: A Systematic Review

et al. 2010

View full text Add to dashboard Cite

show abstract

“…In this regard, many institutions screen renal transplant recipients for polyomavirus infection through the detection of virally loaded epithelial cells (also known as decoy cells) in urine specimens (10). However, polyomavirus shedding in urine is very common and has been demonstrated to occur in 20% to 45% of renal transplant recipients (13)(14)(15)(16)(17)(18). Accordingly, the predictive characteristics of urinary decoy cell shedding are limited (19).…”

mentioning

confidence: 99%

Polyomavirus Polymerase Chain Reaction as a Surrogate Marker of Polyomavirus-Associated Nephropathy

et al. 2007

View full text Add to dashboard Cite

show abstract

Genotypic diversity of polyomaviruses circulating among kidney transplant recipients in Kuwait

Chehadeh

Nampoory

2013

Journal of Medical Virology

View full text Add to dashboard Cite

BK virus (BKV) and JC virus (JCV) are human polyomaviruses that cause asymptomatic latent infections. Under immunosuppression, BKV-associated nephropathy has been documented in Kuwait and elsewhere. Even though different BKV and JCV genotypes with distinct geographical distribution have been described, the genotype of polyomavirus detected in Kuwait is still unknown. The aim of this study was to determine the genotypes of BKV and JCV detected in renal transplant recipients. The detection of polyomavirus DNA was carried out in serum and urine samples of 200 post-transplant recipients during a 1-year follow-up period. Fifty-one (25.5%) post-transplant recipients were tested positive for polyomavirus DNA by semi-nested PCR. JCV DNA could be detected in 29 (57%) patients, and BKV DNA in 22 (43%) patients. In two renal transplant recipients, both BKV and JCV were detected. According to the Bayesian phylogenetic analysis of polyomavirus VP1 sequences, the majority of detected BKV sequences were most closely related to genotypes I and IV, whereas the majority of JCV sequences were most closely related to genotype 3. Polyomavirus VP1 sequences showed strong stability for up to 12 months in most patients; however, in one patient, an amino acid substitution in the BKV VP1 protein was identified over time. The results suggest a close relationship of BKV sequences with the Asian and European strains, and of JCV sequences with the African strains. Long follow-up studies are needed to investigate the association of polyomavirus polymorphism or genotypic shift with the development of nephropathy.

show abstract

BK Virus Nephropathy in Renal Transplant Recipients in Kuwait: A Preliminary Report

Cited by 15 publications

References 3 publications

Treatment of Polyomavirus Infection in Kidney Transplant Recipients: A Systematic Review

Treatment of Polyomavirus Infection in Kidney Transplant Recipients: A Systematic Review

Polyomavirus Polymerase Chain Reaction as a Surrogate Marker of Polyomavirus-Associated Nephropathy

Genotypic diversity of polyomaviruses circulating among kidney transplant recipients in Kuwait

Contact Info

Product

Resources

About